InvestorsHub Logo
Followers 105
Posts 4947
Boards Moderated 0
Alias Born 10/20/2015

Re: mldillon post# 151675

Monday, 03/08/2021 8:20:58 PM

Monday, March 08, 2021 8:20:58 PM

Post# of 232863
The results of CD12 added $5 billion to the value of CytoDyn. It has just not shown up in the market cap....yet.
Let this sink in....all the BP drugs and trials have failed. Only Dexamethasone has shown reliable utility for Covid....it comes with a high price...organ failure.
CytoDyn drug did not fail...it showed remarkable signal...the trial was flawed in several ways as it was designed in the early days of the pandemic. It needed a larger N of critical and a different design.
Most all the other BP trials ended in terminal failure. Most drugs need to have several Phase 3s on the way to approval.
Most of other drugs are not getting that chance.
CytoDyn has a fairly quick and sure path to approval. I can not stress enough the immense value of the knowledge gained in these two prior trials in designing this likely last trial for acute Covid. Then there is the long haulers trial...again Leronlimab is ahead here as well as one of the only drugs in the race.
If this were a scam there would not be a cacophony of shrill voices calling it such.
This is a disruptive drug for a possible multitude of indications. The company has a eccentric CEO .....Steve Jobs was fired at Apple. Everyone thought Elon Musk was an dreamer in the early years and that his vision would never succeed.
Say what you will about Nader but the man has vision.
How many metals did Edison test before he found tungsten?
The short sighted see CD12 as a failure. It is but one step along the way. Nearly all Biotechs face stumbling blocks. Where so many warn of danger is the time and place of opportunity...on the path to success.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News